투후라 바이오사이언시스(HURA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.11 (+0.96%), 시가총액 $0.15B, 52주 최저~최고 $0.44 ~ $3.31.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also
투후라 바이오사이언시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
투후라 바이오사이언시스의 현재 주가는 $2.11 (+0.96%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
투후라 바이오사이언시스의 시가총액은 약 $0.15B입니다.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0,